Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 14, 469 (2008)
doi:10.1038/nm0508-469
Return to the basics might breathe life into HIV vaccine pipeline
Roxanne Khamsi1
- New York
As the financial world grapples with major market corrections, the HIV research community faces its own reality check. The scientific reassessment comes after disappointing results from a candidate HIV vaccine developed by Merck caused the company to halt human trials of the potential vaccine last September.
To read this story in full you will need to login or make a payment (see right).
